Hikma Pharmaceuticals signs a new service agreement in Jordan

Hikma Pharmaceuticals has recently signed a new service agreement with PrimeVigilance, a leading international company that provides pharmacovigilance (PV) and medical information services to gain access to top quality and global-scale PV services. Pharmacovigilance or Drug Safety is the pharmacological science relating to the monitoring, detection and prevention of adverse effects of pharmaceutical products.Under this agreement, Hikma will be able to globalize all its PV operations across its worldwide group of companies, a statement released by the company said.The agreement will also assist Hikma in covering all the regulatory and scientific elements of PV required by health authorities in different countries.In addition, Hikma will better monitor and evaluate the benefit-risk balance of its products, and will be more compliant with the highest standards of quality, international regulations, and codes of best practices. The agreement will also re-enforce Hikma’s commitment to compliance with laws and regulations.Hikma Pharmaceuticals’ CEO Saeed Darwazah, said, “I am pleased to announce this partnership with PrimeVigilance, which will enable us to maintain our highest standards of quality.“Through this partnership, we fulfil our commitment towards ensuring the safety of our patients wherever we operate, and we are always in compliance with all applicable laws and regulations,” Darwazah added.PrimeVigilance CEO Neil Clark said, “We are very pleased to work with Hikma and provide a range of important safety services to support their fast-growing, international operations.”Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma ‘s operations are conducted through three businesses: “Branded”, “Injectables” and “Generics,” based principally in the MENA region, where it is a market leader, the United States and Europe.